Corporate governance
Professional experience:
Founder and Chairman of the Board of Directors of Promomed Group, medical doctor.
Petr Bely has more than 25 years of experience in the medical sector and has held senior positions in a number of large pharmaceutical companies. In 2005, he established the Promomed company and in a few years turned it into one of the most dynamically growing players in the Russian pharmaceutical market.
Petr Bely regularly participates in scientific forums, conferences and other industry events. He is the author of numerous scientific publications. In March 2021, he was awarded the Pirogov Order for his merits in the field of drug production.
Education:
— Moscow State Medical and Dental University, "Medicine" specialty, training in clinical residency and a full course in "Therapeutics" specialty;
— Candidate of Medical Sciences in the "Internal diseases" specialty.
Professional experience:
Investment banker with rich experience, professional manager of major assets. Now he is an international investor, engaged in his own projects, manages a portfolio of personal assets through a family office in Zurich, Switzerland, invests in real estate, media, and venture capital companies.
Education:
— Moscow State University of Foreign Affairs, International Finance Expert;
— ESCP Business School in Paris (ESCP-EAP), communications and information management.
First Vice-Rector for Academic Affairs, Head of the Department of Propaedeutics of Internal Diseases and Gastroenterology of the Evdokimov Moscow State University of Medicine and Dentistry of the Russian Ministry of Health.
His area of expertise includes the problems of gastroenterology and hepatology. Igor Maev is the creator of a well-known scientific school in Russia dealing with the problems of diagnosis and treatment of diseases of the upper gastrointestinal tract.
Since 2016, he has been an academician of the Russian Academy of Sciences, he is the author and co-author of more than 800 scientific papers. Igor Maev is a member of the Presidium of the Russian Gastroenterological Association, a member of the Presidium of the Higher Attestation Commission, a member of the Working Group in the field of education and science at the Commission under the President of the Russian Federation on state awards in the areas of higher school and teachers, etc., as well as a member of the editorial boards of following journals: “Therapeutic Archive”, “Clinical Medicine”, “Russian Journal of Gastroenterology, Hepatology, Coloproctology”, “Experimental and Clinical Gastroenterology”, “Pharmateca”, “Consilium Medicum”, and “Bulletin of the Russian Academy of Medical Sciences”.
Igor Mayev is an Honored Doctor of the Russian Federation, Honored Scientist of the Russian Federation, laureate of the Russian Government award in Science and Technology, the Russian Government award in the field of quality in 2014, the “Excellent Healthcare Worker” badge, the Order of Friendship, the Order of Honor, the Certificate of Honor of the President of the Russian Federation and other awards.
Alexander Efremov graduated from the Military Medical Academy, then postgraduate studies at the Department of Naval and General Therapy. He also graduated from Russian Academy of Public Administration (now RANEPA) in the specialty of State and Municipal Administration. Passed management retraining courses at Harvard University, IMD School and Stanford University.
He has been working in the field of healthcare for more than thirty years: started as a military doctor in the naval personnel of the Northern Fleet of the Armed Forces of the Russian Federation, worked as an adjunct at the Department of Therapy at the Medical Academy, where he defended his PhD thesis in Cardiology, invasive methods of treatment of cardiac arrhythmias. Alexander Efremov worked as a senior resident of the clinic, taught at the department, continued research, helping applicants in the preparation of scientific papers.
Then he joined the pharmaceutical field, where he worked his way up to the General Manager of the representative office, led a number of large foreign pharmaceutical and medical device companies in Russia and the CIS.
In 2022, he joined the Promomed team. In the position of Executive Director he is responsible for shaping the Company's strategy in the commercial segment of the pharmaceutical market, selecting an active product portfolio, launching new products to the markets of Russia and the CIS, operational marketing and promotion of the Company's commercial portfolio.
Alexander Efremov is the author of scientific papers published in Russia and abroad, speaker at industry events, a member of the Strategy Council of one of the Eastern European companies.
Yuri Troyankin graduated from Moscow Institute of Physics and Technology (State University).
He completed professional retraining at the Plekhanov Russian Academy of Economics and Thunderbird American Graduate School of International Management.
He has been working in the field of human resource management for more than 20 years, having worked his way up from a specialist to a top manager in holding-type organizations, industry leaders, including banking/financial institutions, oil industry, mechanical engineering, metallurgy, housing and communal services, construction and real estate, agribusiness, consumer goods industry, and pharmaceutical industry. Yuri Troyankin has a successful experience in building an organization, forming teams and talent management, transforming corporate culture, strategic development and change management.
He joined the Promomed team at the end of 2020. His area of responsibility includes human capital management, organizational development, and transformational processes.
Kira Zaslavskaya has more than 10 years of experience in the medical sector. She started her career as a medical representative and now she is a top manager at a major pharmaceutical company.
In 2009, she joined the team of Promomed Group. As Director for New Products, she is responsible for the product portfolio development strategy, the introduction of new technologies in the development of medicines, the organization of preclinical and clinical trials and the launch of products on the market.
Kira Zaslavskaya participated in the implementation of the world’s largest observational post-marketing study in endocrinlogy of the efficacy and safety of Reduxin®, as well as in the development, study and market launch of Areplivir®, the drug for coronavirus infection.
She graduated from the Mendeleev Russian University of Chemical Technology and passed postgraduate training program at the Nesmeyanov Institute of Organoelement Compounds of the Russian Academy of Sciences. She is an author of numerous scientific papers, a competent speaker at industry events
